首頁
Maze Therapeutics

7月 2026Maze Therapeutics的市場佔有率分析

Last Revised: December 19, 2018 Welcome to Maze! Please read the following terms and conditions of use (the “Terms of Use”) carefully before using this website at www.mazetx.com or its subdomains (this “Website”). Your use of this Website is subject to,...

健康 > 生物技術和製藥

域名mazetx.com

成立年份2019

僱員51 - 200

年度營收$5M - $10M

Maze Therapeutics

Maze Therapeutics（包含公司地區）

mazetx.com

查看更多網站流量與參與度資訊

Maze Therapeutics截至 7月 2026 的總收入為 5M - 10M

Maze Therapeutics 熱門網域產生的總收入

Maze Therapeutics 熱門網域 3 年內的總收入

Maze Therapeutics 熱門網域的總收入

mazetx.com5M - 10M

透過銷售情報查看更多內容

Maze Therapeutics的熱門網域總造訪量

了解Maze Therapeutics市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

mazetx.com14.7K

透過銷售情報查看更多內容

Maze Therapeutics的熱門網域平均造訪時長

分析Maze Therapeutics參與度指標。

過去 3 個月平均造訪時長

子公司細目

mazetx.com00:00:29

透過銷售情報查看更多內容

Maze Therapeutics的熱門網域平均頁面瀏覽量

了解Maze Therapeutics如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

mazetx.com1.65

透過銷售情報查看更多內容

Maze Therapeutics按網域劃分的熱門競爭對手

7月 2026的熱門類似網站，依相似度排名

relaytx.com公司名Relay Therapeutics僱員51 - 200總部美國, 馬薩諸塞州, Cambridge年度營收$50M - $75M訪問總量13.7K健康 > 生物技術和製藥

使用的熱門技術Maze Therapeutics

这些是Maze Therapeutics顶级域名使用的行业网站技术

小工具 (3)

Twemoji

內容管理系統 (2)

WordPress

轉換與分析 (2)

Google Analytics

市場行銷 (2)

Google Marketing Platform

更多技術

7

檢視所有

新聞與訊號來自Maze Therapeutics

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Zifornd partnered with Maze Therapeutics, Inc. on Jan 1st '26.Early this year, Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc announced that they have partnered to solve the critical challenge of managing, storing, and scaling massive, disparate biobank data to help in their quest for precision medicine via AI-powered scientific workflows. https://zifornd.com/news/zifo-and-maze-therapeutics-partner-to-power-precision-medicine/

新聞Maze Therapeutics, Inc. identified as competitor of Vertex Pharmaceuticals.Maze Therapeutics could be set to challenge Vertex Pharmaceuticals as its kidney disease drug has shown benefit in a Phase II trial.

新聞Giwa left Maze Therapeutics, Inc. as Senior Medical Director on Mar 1st '26.Most recently, Dr. Giwa served as Senior Medical Director at Maze Therapeutics, where was the primary clinical lead for a genetic chronic kidney disease program and additional early-stage assets, with responsibility for overall clinical strategy, global trial design, safety oversight, and regulatory positioning.